|Mr. Michael Perfetto||Group VP||604.09k||N/A||56|
|Mr. Ara Aprahamian||Exec. Officer||602k||N/A||N/A|
|Mr. Uday V. Baldota||CEO & Director||N/A||N/A||47|
|Mr. Mariano Balaguer||VP, CFO & Chief Accounting Officer||N/A||N/A||44|
|Mr. Jeff Holm||Exec. Director Sales and Operations||N/A||N/A||N/A|
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Sun Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.